Milestone Pharmaceuticals, Inc. (MIST)

Over the past six months, Milestone Pharmaceuticals' stock price has been impacted by several key events. CARDAMYST received FDA approval in December 2025, which was a positive catalyst, although shares fell the day after the news. In March 2025, the company received a Complete Response Letter (CRL) from the FDA, causing the stock to plunge. The company reported its Q3 2025 and Q4 2025 earnings, highlighting the FDA approval and U.S. launch of CARDAMYST. In mid-December 2025, Wells Fargo and HC Wainwright & Co. both doubled their price targets for MIST. In April 2026, Milestone Pharmaceuticals announced the RESET-PSVT Registry and reported that its EMA Marketing Authorization Application (MAA) for etripamil was accepted. In July and September 2024, Stuart Duty, Andrew Saik and Joseph Papa joined the board as independent directors.

Reliable seasonal analysis for Milestone Pharmaceuticals, Inc. products and services is challenging due to the limited availability of historical data. The seasonal timeframe for MIST is generally in line with the broader Healthcare sector, which typically experiences seasonal strength from April 25 to December 4. Demand for CARDAMYST is likely driven more by patient diagnoses, physician prescriptions, and market access rather than traditional seasonal consumer patterns.

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines, operating within the Healthcare sector, specifically in the Biotechnology industry. Their major product is CARDAMYST™ (etripamil) nasal spray, approved in the United States for the self-administered treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults. The company is also actively developing etripamil for other cardiovascular indications, including atrial fibrillation with rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals, Inc. is headquartered in Montréal, Québec, Canada. Its approved product, CARDAMYST, is available in the United States, and the company also has a presence in Canada.

Milestone Pharmaceuticals' brand reputation has been shaped by the regulatory journey and commercialization of CARDAMYST. The FDA approval of CARDAMYST in December 2025 was a major positive event, representing the first new treatment option in over 30 years for PSVT patients. The company's reputation faced a challenge in March 2025 when it received a Complete Response Letter (CRL) from the FDA for CARDAMYST, which led to a substantial drop in stock price. The company's commitment to addressing the CMC issues and subsequent approval demonstrated its resilience.

Milestone Pharmaceuticals, Inc. has a diverse ownership structure comprising institutional investors, the general public, and company insiders. As of May 7, 2026, there were 87 institutional owners and shareholders holding a total of 26,561,085 shares. Major institutional shareholders include Propel Bio Management, LLC, Adage Capital Partners Gp, L.l.c., RTW Investments, LP, Marshall Wace, Llp, Two Sigma Investments, Lp, Simplify Asset Management Inc., Jane Street Group, Llc, Pathstone Holdings, LLC, Morgan Stanley and Lion Point Capital, LP. As of June 2025, institutional investors held approximately 22.59% of the company's shares, while the general public held about 74.6% as of April 15, 2025. Individual insiders, including CEO Joseph Oliveto, collectively owned 3.79% of the shares as of July 12, 2025.